These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17216836)

  • 1. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 3. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 4. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 6. [New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():60-1. PubMed ID: 15373052
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 8. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 9. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ
    HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
    [No Abstract]   [Full Text] [Related]  

  • 10. Aptivus capsules granted full FDA approval.
    AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
    [No Abstract]   [Full Text] [Related]  

  • 11. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 13. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
    Soler-Palacín P; Fàbrega A; María López R; Figueras C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
    [No Abstract]   [Full Text] [Related]  

  • 16. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA approves Aptivus (tipranavir).
    Pham PA
    Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV agents. Tipranavir for treatment-experienced PHAs.
    TreatmentUpdate; 2007 Jan; 19(1):8. PubMed ID: 17390481
    [No Abstract]   [Full Text] [Related]  

  • 19. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
    AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
    [No Abstract]   [Full Text] [Related]  

  • 20. Aptivus in the hotseat. Excerpts from the FDA hearings.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.